Enhancing Capital’s AbbVie ABBV Stock Holding History

Enhancing Capital’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$524K	Buy	2,004 +4	+0.2%	+$1.02K	0.36%	54
2026 Q2	$503K	Hold	2,000	–	–	0.35%	60
2026 Q1	$435K	Hold	2,000	–	–	0.32%	62
2025 Q4	$457K	Hold	2,000	–	–	0.33%	63
2025 Q3	$463K	Hold	2,000	–	–	0.34%	66
2025 Q2	$371K	Hold	2,000	–	–	0.28%	75
2025 Q1	$419K	Hold	2,000	–	–	0.34%	72
2024 Q4	$355K	Buy	+2,000	New	+$368K	0.28%	75
2022 Q3	$278K	Hold	2,000	–	–	0.34%	64
2022 Q2	$306K	Hold	2,000	–	–	0.37%	61
2022 Q1	$324K	Hold	2,000	–	–	0.35%	64
2021 Q4	$271K	Buy	+2,000	New	+$236K	0.29%	69

Other funds holding ABBV

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return

DekaBank Deutsche Girozentrale Frankfurt, Germany $87.8B AUM 20.94% 1-Year Est. Return

Swedbank Stockholm, Sweden $118B AUM 40.52% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $52.9B AUM 36.03% 1-Year Est. Return

ProShare Advisors Bethesda, Maryland $69.5B AUM 31.38% 1-Year Est. Return

Asset Management One Tokyo, Japan $40B AUM 30.45% 1-Year Est. Return

Cardano Risk Management Rotterdam, Netherlands $18.2B AUM 38.97% 1-Year Est. Return

Sepio Capital Salt Lake City, Utah $2.5B AUM 20.77% 1-Year Est. Return

Enhancing Capital's ABBV Position: Q3 2026 in Review

Enhancing Capital increased its AbbVie (ABBV) stake by 0.2% in Q3 2026, buying an estimated $1.02K and bringing the position to 2,004 shares worth $524K. The position accounts for 0.36% of the portfolio, ranked #54.

Enhancing Capital first reported a position in ABBV in Q4 2021 and has held it in 12 quarters since. 1,900 funds tracked by Wall St. Rank hold ABBV as of Q3 2026.

Enhancing Capital held 2,004 shares of AbbVie worth $524K as of Q3 2026.
Enhancing Capital bought 4 AbbVie shares in Q3 2026, an estimated $1.02K.
AbbVie made up 0.36% of Enhancing Capital's portfolio in Q3 2026, its #54 holding.
Enhancing Capital first reported a position in AbbVie in Q4 2021 and has held it in 12 quarters since.
1,900 funds tracked by Wall St. Rank held AbbVie as of Q3 2026.

Based on Enhancing Capital's 13F filing for Q3 2026, filed 26 Oct 2026.